4 results
To establish the safety profile of daratumumab when given in combination with bortezomib and dexamethasone in subjects with relapsed or refractory MM
To compare the number of responders to vaccination with pneumococcal and conjugated Hib vaccine at different time points after last dose of rituximab, to investigate what the ideal moment of vaccination would be. Secondly to study the immune-…
To investigate what the ideal moment to vaccinate would be, early (after 2-6 months) or late (after 9-12 months) after cessation of rituximab. Secondly to study the immune-response to vaccination with influenza virus vaccine after treatment with…
Primary ObjectivesPhase 2The primary objectives of Phase 2 are:• To evaluate short- and long-term safety and tolerability of SNDX 5613.• To assess the CR+CRh rate. Secondary ObjectivesPhase 2Secondary objectives of Phase 2 are:• • To assess…